ReviewBMC medicine2012
Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals.
Review in BMC medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pre-Clinical Alzheimer's (ALZ) Diagnosis (PCD) = Optimum Outcomes (OO)
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI) as a Pre-Clinical or Pro-Dromal Alzheimers Diagnosis (Prognosis) for Optimum Outcomes
Who cites it
19 citing papers in PubMed.
- Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial.Current Alzheimer research · 2017Trial
- VR-based path integration predicts individual risk of rapid cortical decline: a one-year longitudinal study in cognitively unimpaired adults.Alzheimer's research & therapy · 2026Article
- APOE4-Aβ synergy drives brain network dysfunction and neuronal lysosomal-ER proteostasis dysregulation a preclinical Alzheimer's disease model.bioRxiv : the preprint server for biology · 2025Article
- Article
- When Does Alzheimer's Disease Really Start? The Role of Biomarkers.International journal of molecular sciences · 2019Review
- Subregional Density of Neurons, Neurofibrillary Tangles and Amyloid Plaques in the Hippocampus of Patients With Alzheimer's Disease.Frontiers in neuroanatomy · 2019Article
- A Study of Amyloid-β and Phosphotau in Plaques and Neurons in the Hippocampus of Alzheimer's Disease Patients.Journal of Alzheimer's disease : JAD · 2018Article
- MEG biomarker of Alzheimer's disease: Absence of a prefrontal generator during auditory sensory gating.Human brain mapping · 2017Article
- Hippocampal and Amygdala Gray Matter Loss in Elderly Controls with Subtle Cognitive Decline.Frontiers in aging neuroscience · 2017Article
- Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2016Review
- Imaging biomarkers associated with cognitive decline: a review.Biological psychiatry · 2015Review
- Relationship between Brain Age-Related Reduction in Gray Matter and Educational Attainment.PloS one · 2015Article
- Genetic evidence for the involvement of variants at APOE, BIN1, CR1, and PICALM loci in risk of late-onset Alzheimer's disease and evaluation for interactions with APOE genotypes.Journal of molecular neuroscience : MN · 2014Article
- Changes in PINCH levels in the CSF of HIV+ individuals correlate with hpTau and CD4 count.Journal of neurovirology · 2014Article
- Efficient derivation of cortical glutamatergic neurons from human pluripotent stem cells: a model system to study neurotoxicity in Alzheimer's disease.Neurobiology of disease · 2014Article
- Altered proteolysis in fibroblasts of Alzheimer patients with predictive implications for subjects at risk of disease.International journal of Alzheimer's disease · 2014Article
- Selective alterations of neurons and circuits related to early memory loss in Alzheimer's disease.Frontiers in neuroanatomy · 2014Article
- Neuroimaging of dementia in 2013: what radiologists need to know.European radiology · 2013Review
- Free Recall Episodic Memory Performance Predicts Dementia Ten Years prior to Clinical Diagnosis: Findings from the Betula Longitudinal Study.Dementia and geriatric cognitive disorders extraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the first description of the case of Auguste Deter, presented in Tübingen in 1906 by Alois Alzheimer, there has been an exponential increase in our knowledge of the neuropathological, cellular, and molecular foundation of Alzheimer's disease (AD). The concept of AD pathogenesis has evolved from a static, binary view discriminating cognitive normality from dementia, towards a dynamic view that considers AD pathology as a long-lasting morbid process that takes place progressively over years, or even decades, before the first symptoms become apparent, and thus operating in a continuum between the two aforementioned extreme states. Several biomarkers have been proposed to predict AD-related cognitive decline, initially in cases with mild cognitive impairment, and more recently in cognitively intact individuals. These early markers define at-risk individuals thought to be in the preclinical phase of AD. However, the clinical relevance of this preclinical phase remains controversial. The fate of such individuals, who are cognitively intact, but positive for some early AD biomarkers, is currently uncertain at best. In this report, we advocate the point of view that although most of these preclinical cases will evolve to clinically overt AD, some appear to have efficient compensatory mechanisms and virtually never develop dementia. We critically review the currently available early AD markers, discuss their clinical relevance, and propose a novel classification of preclinical AD, designating these non-progressing cases as 'stable asymptomatic cerebral amyloidosis'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.